Erythropoiesis-Stimulating Agent (ESA) Practice Patterns in Patients with Chemotherapy-Induced Anemia (CIA) Treated at Hospital Oncology Clinics

Abstract

Objectives

To characterize erythropoiesis-stimulating agent (ESA) usage initiated in hospital outpatient oncology centers that employ weekly (QW) and every-3-week (Q3W) ESA dosing regimens; describe the frequency of ESA dosing, transfusions, hemoglobin determinations, and anemia-related visits between these 2 regimens; and compare the rates at which inpatient ESA doses are administered on QW versus Q3W schedules.

Methods

This was a retrospective, observational record review evaluating ESA usage in 641 patients from 8 outpatient oncology clinics throughout the United States. Adult patients who initiated myelosuppressive chemotherapy for a documented solid tumor between August 1, 2007 and June 30, 2009 and received their first 3 consecutive outpatient ESA doses on a QW or Q3W schedule were eligible for study inclusion. During a single course of chemotherapy, ESA administrations were recorded as long as ESA therapy was continued on the initial regimen. ESA doses were captured until termination of ESA therapy, until 9 months had elapsed since the first ESA dose, until the patient was switched to another ESA regimen, or until death. ESA administration during inpatient admissions was also recorded.

Results

ESA utilization varied between the dosing groups, with fewer ESA doses administered per follow-up month in patients receiving Q3W versus QW ESA therapy (mean, 1 vs 2 doses). Compared to weekly administration, extended-dose ESA therapy also reduced the number of hemoglobin determinations and anemia-related visits without chemotherapy required per follow-up month. Neither the number of transfusions nor the number of packed red blood cell units administered per follow-up month differed between treatment groups. Compared to weekly ESA therapy, Q3W administration reduced costs associated with ESA prescribing and utilization.

Conclusion:

Extended-dose ESA therapy (Q3W dosing) may improve practice efficiency and may be associated with reduced frequencies of hemoglobin determinations and ESA doses required. Q3W dosing may also reduce inpatient ESA utilization by reducing the number of ESA doses required for previously maintained outpatients.

Keywords

anemia erythropoiesis-stimulating agents ESA inpatient outpatient

Get full access to this article

View all access options for this article.

References

Schwartz

. Anemia in patients with cancer: incidence, causes, impact, management, and use of treatment guidelines and protocols. Am J Health Syst Pharm. 2007;64(suppl 2):S5–13.

Cella

Dobrez

Glaspy

Control of cancer-related anemia with erythropoietic agents: a review of evidence for improved quality of life and clinical outcomes. Ann Oncol. 2003;14(4):511–519.

Bohelius

Wilson

Seidenfield

. Ertyhropoeitan or darabepoetin for patients with cancer. Cochrane Database Syst Rev. 2006;3:CD003497. doi: 10,1002/14 CD003407.pub4.

Minton

Stone

Richardson

. Drug therapy for the management of cancer related fatigue. Cochrane Database Syst Rev. 2008;1:CD006704. doi: 10.1002/14651858.CD006704.pub2

Janssen and Amgen. ESA APPRISE Oncology Program. https://www.esa-apprise.com/ESAAppriseUI/ESAAppriseUI/default.jsp

Procrit [package insert]. Raritan, NJ: Ortho Biotech Products, LP; 2011.

Aranesp [package insert]. Thousand Oaks, CA: Amgen, Inc., 2011.

National Comprehensive Cancer Network. Cancer- and chemotherapy-induced anemia. http://www.nccn.org/professionals/physician_gls/pdf/anemia.pdf. Accessed October 4, 2011.

Rizzo

Somerfield

Hagerty

. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol. 2008;26(1):132–148.

10.

US Department of Health and Human Services Centers for Medicare and Medicaid Services. Medicare posts final national coverage determination for the use of erythropoiesis stimulating agents. www.cms.hhs.gov. Accessed October 4, 2011.

11.

Herrington

Tomita

Green

. Utilization of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia. Am J Heath Syst Pharm. 2005;62(10):54–62.

12.

Beveridge

Rifkin

Moleski

. Impact of long-acting growth factors on practice dynamics and patient satisfaction. Pharmacotherapy. 2003;23:S101–109.

13.

Griffith

Allen

Pultz

Penza

The impact of a long-acting erythropoiesis stimulating protein on patient throughput in a hospital-based oncology clinic. Hosp Pharm. 2008;43:388–395.

14.

Amara

Lew

Adamson

. Optimizing anemia management through medication reconciliation: applying the 2010 Joint Commission patient safety goal requirements. P T. 2010;25(3):165–174.

15.

Muller

Baribeault

Extended-dosage-interval regimens of erythropoietic agents in chemotherapy-induced anemia. Am J Health Syst Pharm. 2007;64:2547–2556.

16.

Johnson

Dahlman

Eng

. NCCN Oncology Risk Evaluation and Mitigation Strategies White Paper: recommendations for stakeholders. National Comprehensive Cancer Network. 2010. http://www.jnccn.org/content/8/Suppl_7/S-7.full#abstract-1 .